Global Chondrosarcoma – Pipeline Insight and Therapeutic Assessment Reviewed in 2017

Posted on 2017-11-27 by Mark Hub in Pharmaceuticals // 0 Comments

Market Research Hub

Albany, US, 2017-Nov-27 — /EPR Network/ —A fresh report has been added to the wide database of Market Research Hub (MRH). The research study is titled “Chondrosarcoma – Pipeline Review, H2 2017”which encloses important data about the production, consumption, revenue and market share, merged with information related to the market scope and product overview. The report anticipates that the sector for pharmaceutical industry would rise at a positive CAGR during the period 2017-2022.

Click here for Free Sample Report@https://www.marketresearchhub.com/enquiry.php?type=S&repid=1381805

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma – Pipeline Review, H2 2017, provides an overview of the Chondrosarcoma (Oncology) pipeline landscape.

Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Chondrosarcoma – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chondrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chondrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Chondrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Chondrosarcoma (Oncology).
– The pipeline guide reviews pipeline therapeutics for Chondrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Chondrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Chondrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Chondrosarcoma (Oncology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Chondrosarcoma (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Chondrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report with TOC@ https://www.marketresearchhub.com/report/chondrosarcoma-pipeline-review-h2-2017-report.html

Table of Contents

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chondrosarcoma – Overview 7
Chondrosarcoma – Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Chondrosarcoma – Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Chondrosarcoma – Companies Involved in Therapeutics Development 21
Agios Pharmaceuticals Inc 21
Celgene Corp 21
Daiichi Sankyo Co Ltd 22
Epizyme Inc 22
Horizon Pharma Plc 23
Karyopharm Therapeutics Inc 23
Merck & Co Inc 24
Nektar Therapeutics 24
Novartis AG 25
Ono Pharmaceutical Co Ltd 25
Pfizer Inc 26
Chondrosarcoma – Drug Profiles 27
12-B80 – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
aldoxorubicin hydrochloride – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
axitinib – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
DS-1001 – Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
enasidenib mesylate – Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
galarmin – Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
interferon gamma-1b – Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
ivosidenib – Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
nivolumab – Drug Profile 73

Continued…..

Enquire about this Report@ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1381805

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceutical industry reports and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick